

Self-Assembled Tat Nanofibers as Effective Drug Carrier and Transporter

*Pengcheng Zhang, Andrew G. Cheetham, Yi-An Lin, Honggang Cui**

Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, MD 21218, United States

*Email: hcui6@jhu.edu

CONTENTS

Figure S1. Characterization of mC ₈ -Tat	S2
Figure S2. Characterization of dC ₈ -Tat	S3
Figure S3. Characterization of qC ₈ -Tat	S4
Figure S4. Wide angle X-ray scattering of Tat nanofibers	S5
Figure S5. TEM of qC ₈ -Tat nanofiber in DPBS	S6
Figure S6. TEM of qC ₈ -Tat nanofiber loaded with PTX (100:1, mol/mol)	S7
Figure S7. TEM of qC ₈ -Tat nanofiber loaded with PTX (20:1, mol/mol)	S8
Figure S8. TEM of qC ₈ -Tat nanofiber loaded with PTX (10:1, mol/mol)	S9
Figure S9. TEM of qC ₈ -Tat nanofiber loaded with PTX (20:3, mol/mol)	S10
Figure S10. TEM of qC ₈ -Tat nanofiber loaded with PTX (5:1, mol/mol)	S11
Table S1. The measured diameters of PTX-N with different drug loading	S12
Figure S11. CD spectra of Tat nanofibers and PTX-N	S13
Figure S12. The cellular uptake of coumarin-6 or C6-N by KB-3-1	S14
Figure S13. The cellular uptake of Flutax-2 or Flutax-2-N by KB-3-1	S15
Figure S14. Cytotoxicity of PTX-N to A549	S16
Figure S15. Cytotoxicity of PTX-N to MDA-MB-231	S17
Figure S16. Cytotoxicity of PTX-N to OVCAR-8	S18
Figure S17. Subcellular localization of free coumarin-6 in KB-3-1 cells	S19
Figure S18. Subcellular localization of free Flutax-2 in KB-3-1 cells	S20




Figure S1. RP-HPLC (a) and MALDI-TOF MS (b) characterization of mC₈-Tat. The RP-HPLC spectrum confirms the purity of the product (>99%). The peaks at 922.952, 1843.826, and 1866.824 correspond to [M+2H]²⁺, [M+H]⁺ and [M+Na]⁺, respectively.




Figure S2. RP-HPLC (a) and MALDI-TOF MS (b) characterization of dC₈-Tat. The RP-HPLC spectrum confirms the purity of the product (>99%). The peaks at 2099.105 and 2121.069 correspond to [M+H]⁺ and [M+Na]⁺, and other peaks are the isotopic peak of [M+H]⁺.




Figure S3. RP-HPLC (a) and MALDI-TOF MS (b) characterization of qC₈-Tat. The RP-HPLC spectrum confirms the purity of the product (>99%). The peaks at 2607.591 and 2629.610 correspond to [M+H]⁺ and [M+Na]⁺, and other peaks are the isotopic peak of [M+H]⁺.




Figure S4. Wide angle X-ray scattering 2-D pattern collected from an aqueous solution of Tat nanofibers. The reflection (marked with black arrow) corresponds to a d -spacing of 4.7 Å, a signature for β -sheet assemblies. The observation of two arcs instead of a Debye-Scherrer ring is due to the alignment of Tat nanofiber by pipetting during the sample preparation.




Figure S5. TEM image of nanofibers formed by qC₈-Tat in DPBS at 2 mM. Uranyl acetate (2 wt%) was used as a negative staining agent




Figure S6. TEM image of nanofibers formed by mixing qC₈-Tat (2 mM) with PTX at a molar ratio of 100:1 in DPBS. Uranyl acetate (2 wt%) was used as a negative staining agent




Figure S7. TEM image of nanofibers formed by mixing qC₈-Tat (2 mM) with PTX at a molar ratio of 20:1 in DPBS. Uranyl acetate (2wt%) was used as a negative staining agent.




Figure S8. TEM image of nanofibers formed by mixing of qC₈-Tat (2 mM) with PTX at a molar ratio of 10:1 in DPBS. Uranyl acetate (2 wt%) was used as a negative staining agent.




Figure S9. TEM image of nanofibers formed by mixing qC₈-Tat (2 mM) with PTX at a molar ratio of 20:3 in DPBS. Uranyl acetate (2 wt%) was used as a negative staining agent.




Figure S10. TEM image of nanofibers formed by mixing qC₈-Tat (2 mM) with PTX at a molar ratio of 5:1 in DPBS. Uranyl acetate (2 wt%) was used as a negative staining agent.

Table S1. The diameters of PTX-N with different drug loading. Data were presented as mean \pm s.d. ($n = 30$).

Conjugate to PTX ratio, (mol/mol)	No drug	100:1	20:1	10:1	20:3	5:1
Diameter (nm)	15.0 \pm 0.9	14.9 \pm 0.9	14.9 \pm 0.8	15.0 \pm 0.7	15.0 \pm 0.8	14.8 \pm 0.7




Figure S11. Normalized CD spectra of 400 μM blank Tat nanofibers (BN) and Tat nanofibers loaded with PTX (PTX-N, 10:1, mol/mol) in DPBS. Both the blank nanofiber and PTX-N showed signal at around 205 nm indicating a polyproline type II (PPII) like conformation. This experiment suggests that Tat peptides are not accountable for the observed change in nanofiber morphology




Figure S12. Time-course intracellular accumulation of coumarin-6 in KB-3-1 cells after incubation with either 300 nM free coumarin-6 (C6) or coumarin-6 loaded nanofibers (C6-N) for 0.5, 1 and 4 h, as determined by flow cytometry. While the intracellular accumulation kinetics between C6 and C6-N is different, comparable accumulation was achieved after 4 h incubation.




Figure S13. Time-course intracellular accumulation of Flutax-2 in KB-3-1 cells after incubation with either 500 nM free Flutax-2 or Flutax-2 loaded nanofibers (Flutax-2-N) for 0.5, 1 and 4 h, as determined by flow cytometry. The intracellular accumulation of Flutax-2-N is more efficient than free Flutax-2.




Figure S14. Cell viability of A549 non-small cell lung cancer cells treated for 48 h with PTX (0.01 – 250 nM), PTX-N (0.01 – 250 nM PTX and 0.1 – 2500 nM qC₈-Tat), or qC₈-Tat (0.1 – 2500 nM qC₈-Tat). Comparable cytotoxicity was observed for free PTX and PTX-N, indicating encapsulation did not reduce the antitumor activity of paclitaxel to A549. qC₈-Tat did not contribute to the cytotoxicity significantly at the concentrations used for paclitaxel encapsulation.




Figure S15. Cell viability of MDA-MB-231 breast cancer cells treated for 48 h with PTX (0.01 – 250 nM), PTX-N (0.01 – 250 nM PTX and 0.1 – 2500 nM qC₈-Tat), or qC₈-Tat (0.1 – 2500 nM qC₈-Tat). Comparable cytotoxicity was observed for free PTX and PTX-N, indicating encapsulation did not reduce the antitumor activity of paclitaxel to MDA-MB-231. qC₈-Tat did not contribute to the cytotoxicity significantly at the concentrations used for paclitaxel encapsulation.




Figure S16. Cell viability of OVCAR-8 ovarian cancer cells treated for 48 h with PTX (0.01 – 250 nM), PTX-N (0.01 – 250 nM PTX and 0.1 – 2500 nM qC₈-Tat), or qC₈-Tat (0.1 – 2500 nM qC₈-Tat). Comparable cytotoxicity was observed for free PTX and PTX-N, indicating encapsulation did not reduce the antitumor activity of paclitaxel. qC₈-Tat did not contribute to the cytotoxicity significantly at the concentrations used for paclitaxel encapsulation.




Figure S17. Subcellular colocalization of free coumarin-6 (green) in live KB-3-1 with lysosome (Lysotracker red, red) and nucleus (Hoechst 33342, blue) after incubation of cells with 0.3 μ M of coumarin-6 for 0.5, 1, and 4 h at 37 °C. This experiment reveals clearly coumarin-6 dominantly accumulated in the cell membrane even after 4 h incubation, in sharp contrast to courmarin-6 delivered by Tat nanofibers which accumulated largely within the cells.




Figure S18. Subcellular colocalization of free Flutax-2 (green) in live KB-3-1 with lysosome (Lysotracker red, red) and nucleus (Hoechst 33342, blue) after incubation of cells with 0.5 μ M of Flutax-2 for 0.5, 1, and 4 h at 37 °C. This experiment reveals lower intracellular accumulation of free Flutax-2 compared with Flutax-2-N. The co-localization of Flutax-2 (green) with lysosome (red) indicates that free Flutax-2 did not enter the cells through free diffusion.